Viridian Therapeutics (VRDN) News Today

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Up 8.8%

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 7,920,000 shares, a decline of 15.7% from the June 15th total of 9,390,000 shares. Based on an average daily trading volume, of 943,400 shares, the days-to-cover ratio is presently 8.4 days.

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and ten have issued a bu

Viridian Therapeutics (NASDAQ:VRDN) Shares Up 5.6%

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have assigne

Perceptive Advisors LLC grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 71.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,730,212 shares of the company's stock aft

Octagon Capital Advisors LP reduced its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 41.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 620,000 shares of the company's stock aft

Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 2.7%

Commodore Capital LP decreased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,924,074 shares of the company's stock after s

Viridian Therapeutics (NASDAQ:VRDN) Trading Up 4.1%

Wolfe Research started coverage on shares of Viridian Therapeutics in a research note on Tuesday. They issued an "outperform" rating and a $29.00 price target for the company.

Kynam Capital Management LP lowered its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 607,915 shares of the company'

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down to $12.17

Vestal Point Capital LP acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,000,000 shares of the company's stock, val

RTW Investments LP acquired a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 605,816 shares of the company's stock, valued at approximately $13,195,000. RTW Inv

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up to $12.34

The Goldman Sachs Group started coverage on Viridian Therapeutics in a report on Thursday. They set a "buy" rating and a $23.00 price objective for the company.

Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5%

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for Viridian Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the compan

HC Wainwright lowered their target price on shares of Viridian Therapeutics from $37.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday.

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down Following Analyst Downgrade

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.28. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The firm's revenue was down 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.61) EPS.

LADENBURG THALM/SH SH downgraded Viridian Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday.